Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PG, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK.

Cancer Discov. 2019 Jul 17. pii: CD-19-0442. doi: 10.1158/2159-8290.CD-19-0442. [Epub ahead of print]

PMID:
31315834
2.

Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, McEwen R, Ratnayake J, Maudsley R, Carr TH, de Bruin EC, Schiavon G, Oliveira M, Turner NC.

Ann Oncol. 2019 Mar 12. pii: mdz085. doi: 10.1093/annonc/mdz085. [Epub ahead of print]

3.

Circadian clock components control daily growth activities by modulating cytokinin levels and cell division-associated gene expression in Populus trees.

Edwards KD, Takata N, Johansson M, Jurca M, Novák O, Hényková E, Liverani S, Kozarewa I, Strnad M, Millar AJ, Ljung K, Eriksson ME.

Plant Cell Environ. 2018 Jun;41(6):1468-1482. doi: 10.1111/pce.13185. Epub 2018 Apr 15.

4.

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.

Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, Ashworth A, Lord CJ.

Sci Data. 2017 Mar 1;4:170020. doi: 10.1038/sdata.2017.20.

5.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

6.

Overview of Target Enrichment Strategies.

Kozarewa I, Armisen J, Gardner AF, Slatko BE, Hendrickson CL.

Curr Protoc Mol Biol. 2015 Oct 1;112:7.21.1-23. doi: 10.1002/0471142727.mb0721s112. Review.

PMID:
26423591
7.

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.

Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, Kozarewa I, Gonzalez de Castro D, Bhosle J, O'Brien M, Turner NC, Popat S, Downward J.

PLoS One. 2015 Sep 28;10(9):e0139074. doi: 10.1371/journal.pone.0139074. eCollection 2015.

8.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728
9.

Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.

Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A.

J Pathol. 2015 Jun;236(2):186-200. doi: 10.1002/path.4517. Epub 2015 Apr 2.

PMID:
25692405
10.

Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.

Dryden NH, Broome LR, Dudbridge F, Johnson N, Orr N, Schoenfelder S, Nagano T, Andrews S, Wingett S, Kozarewa I, Assiotis I, Fenwick K, Maguire SL, Campbell J, Natrajan R, Lambros M, Perrakis E, Ashworth A, Fraser P, Fletcher O.

Genome Res. 2014 Nov;24(11):1854-68. doi: 10.1101/gr.175034.114. Epub 2014 Aug 13.

11.

Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress.

McDade SS, Patel D, Moran M, Campbell J, Fenwick K, Kozarewa I, Orr NJ, Lord CJ, Ashworth AA, McCance DJ.

Nucleic Acids Res. 2014 Jun;42(10):6270-85. doi: 10.1093/nar/gku299. Epub 2014 May 13.

12.

Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.

Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D, Govindasami K, Guy M, Sawyer E, Wilkinson R; UKGPCS Collaborators, Antoniou AC, Eeles R, Kote-Jarai Z.

Br J Cancer. 2014 Mar 18;110(6):1663-72. doi: 10.1038/bjc.2014.30. Epub 2014 Feb 20.

13.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

14.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
15.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.

Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.

16.

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.

Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.

17.

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.

Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A.

PLoS One. 2013 Apr 25;8(4):e61520. doi: 10.1371/journal.pone.0061520. Print 2013.

18.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.

Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. No abstract available.

PMID:
23524863
19.

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.

J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.

PMID:
23165508
20.

Genomic characterisation of acral melanoma cell lines.

Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R.

Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92. doi: 10.1111/j.1755-148X.2012.01016.x.

PMID:
22578220
21.

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ.

Blood. 2012 Aug 2;120(5):1077-86. doi: 10.1182/blood-2012-03-412981. Epub 2012 May 9.

22.

Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation.

McDade SS, Henry AE, Pivato GP, Kozarewa I, Mitsopoulos C, Fenwick K, Assiotis I, Hakas J, Zvelebil M, Orr N, Lord CJ, Patel D, Ashworth A, McCance DJ.

Nucleic Acids Res. 2012 Aug;40(15):7190-206. doi: 10.1093/nar/gks389. Epub 2012 May 9.

23.

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.

Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, Sims D, Mitsopoulos C, Fenwick K, Kozarewa I, Naceur-Lombarelli C, Zvelebil M, Isacke CM, Lord CJ, Ashworth A, Hnatyszyn HJ, Pegram M, Lippman M.

Breast Cancer Res Treat. 2012 Aug;135(1):79-91. doi: 10.1007/s10549-012-2068-7. Epub 2012 Apr 26.

PMID:
22535017
24.

A modified method for whole exome resequencing from minimal amounts of starting DNA.

Kozarewa I, Rosa-Rosa JM, Wardell CP, Walker BA, Fenwick K, Assiotis I, Mitsopoulos C, Zvelebil M, Morgan GJ, Ashworth A, Lord CJ.

PLoS One. 2012;7(3):e32617. doi: 10.1371/journal.pone.0032617. Epub 2012 Mar 5. Erratum in: PLoS One. 2012;7(4): doi/10.1371/annotation/5b071c93-9fa8-4be6-9cbd-95aead146305. J, Christopher [corrected Lord, Christopher J].

25.

A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'Hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Stern MH, Reis-Filho JS.

J Pathol. 2012 May;227(1):29-41. doi: 10.1002/path.4003. Epub 2012 Feb 23.

26.

Whole genome sequencing of matched primary and metastatic acral melanomas.

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, Mackay A, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS, Marais R.

Genome Res. 2012 Feb;22(2):196-207. doi: 10.1101/gr.125591.111. Epub 2011 Dec 19.

27.

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

Ha KC, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, Foulkes WD.

BMC Med Genomics. 2011 Oct 27;4:75. doi: 10.1186/1755-8794-4-75.

28.

High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing.

Sims D, Mendes-Pereira AM, Frankum J, Burgess D, Cerone MA, Lombardelli C, Mitsopoulos C, Hakas J, Murugaesu N, Isacke CM, Fenwick K, Assiotis I, Kozarewa I, Zvelebil M, Ashworth A, Lord CJ.

Genome Biol. 2011 Oct 21;12(10):R104. doi: 10.1186/gb-2011-12-10-r104.

29.

High altitude adaptation in Daghestani populations from the Caucasus.

Pagani L, Ayub Q, MacArthur DG, Xue Y, Baillie JK, Chen Y, Kozarewa I, Turner DJ, Tofanelli S, Bulayeva K, Kidd K, Paoli G, Tyler-Smith C.

Hum Genet. 2012 Mar;131(3):423-33. doi: 10.1007/s00439-011-1084-8. Epub 2011 Sep 9.

30.

Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.

Barber LJ, Rosa Rosa JM, Kozarewa I, Fenwick K, Assiotis I, Mitsopoulos C, Sims D, Hakas J, Zvelebil M, Lord CJ, Ashworth A.

PLoS One. 2011;6(7):e21639. doi: 10.1371/journal.pone.0021639. Epub 2011 Jul 5.

31.

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.

Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2730-5. doi: 10.1073/pnas.1018872108. Epub 2011 Apr 11.

32.

96-plex molecular barcoding for the Illumina Genome Analyzer.

Kozarewa I, Turner DJ.

Methods Mol Biol. 2011;733:279-98. doi: 10.1007/978-1-61779-089-8_20.

PMID:
21431778
33.

Amplification-free library preparation for paired-end Illumina sequencing.

Kozarewa I, Turner DJ.

Methods Mol Biol. 2011;733:257-66. doi: 10.1007/978-1-61779-089-8_18.

PMID:
21431776
34.

Whole genome sequencing highlights genetic changes associated with laboratory domestication of C. elegans.

Weber KP, De S, Kozarewa I, Turner DJ, Babu MM, de Bono M.

PLoS One. 2010 Nov 11;5(11):e13922. doi: 10.1371/journal.pone.0013922.

35.

Circadian clock components regulate entry and affect exit of seasonal dormancy as well as winter hardiness in Populus trees.

Ibáñez C, Kozarewa I, Johansson M, Ogren E, Rohde A, Eriksson ME.

Plant Physiol. 2010 Aug;153(4):1823-33. doi: 10.1104/pp.110.158220. Epub 2010 Jun 8.

36.

Alteration of PHYA expression change circadian rhythms and timing of bud set in Populus.

Kozarewa I, Ibáñez C, Johansson M, Ogren E, Mozley D, Nylander E, Chono M, Moritz T, Eriksson ME.

Plant Mol Biol. 2010 May;73(1-2):143-56. doi: 10.1007/s11103-010-9619-2. Epub 2010 Mar 13.

PMID:
20229130
37.

Target-enrichment strategies for next-generation sequencing.

Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, Howard E, Shendure J, Turner DJ.

Nat Methods. 2010 Feb;7(2):111-8. doi: 10.1038/nmeth.1419. Review.

PMID:
20111037
38.

Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes.

Kozarewa I, Ning Z, Quail MA, Sanders MJ, Berriman M, Turner DJ.

Nat Methods. 2009 Apr;6(4):291-5. doi: 10.1038/nmeth.1311. Epub 2009 Mar 15.

39.

A large genome center's improvements to the Illumina sequencing system.

Quail MA, Kozarewa I, Smith F, Scally A, Stephens PJ, Durbin R, Swerdlow H, Turner DJ.

Nat Methods. 2008 Dec;5(12):1005-10. doi: 10.1038/nmeth.1270.

Supplemental Content

Loading ...
Support Center